Utility of 68Ga-PSMA-11 PET/CT in Imaging of Glioma—A Pilot Study

Clinical Nuclear Medicine - Tập 43 Số 9 - Trang e304-e309 - 2018
Arun Sasikumar1, Raghava Kashyap2, Ajith Joy1, Kanhu Charan Patro3, Parthasarathy Bhattacharya3, Venkata Krishna Reddy Pilaka3, Karuna Elza Oommen4, M.R.A. Pillai1
1Department of Nuclear Medicine and PET, KIMS-DDNMRC, KIMS Hospital, Kerala;
2Nuclear Medicine and PET, and
3Radiotherapy, Mahatma Gandhi Cancer Hospital and Research Center, Andhra Pradesh; and
4Department of Nuclear Medicine and PET, St Gregorios International Cancer Care Centre, Kerala, India.

Tóm tắt

Background Imaging of gliomas remains challenging. The aim of the study was to assess the feasibility of using 68Ga-PSMA-11 PET/CT for imaging gliomas. Methods Fifteen patients with glioma from 2 centers were included in the study. Ten patients were treated cases of glioblastoma with suspected recurrence. Two patients were sent for assessing the nature (primary lesion/metastasis) of space-occupying lesion in the brain; 3 patients were imaged immediately after surgery and before radiotherapy. Target-to-background ratios (TBR) for the brain lesions were calculated using contralateral cerebellar uptake as background. Results Among the 10 cases with suspected recurrence, scan was positive in 9, subsequent surgery was done, and histopathology proved it to be true recurrence. In the scan-negative case on follow-up, no evidence of disease could be made clinically or radiologically. Among the other cases the presence or absence of disease could be unequivocally identified on the 68Ga-PSMA-11 brain scan and correlated with the histopathology or other imaging. Apart from the visual assessment quantitative assessment of the lesions with TBR also showed a significantly high TBR value for those with true disease compared with those with no disease. Conclusions In the evaluation of gliomas, 68Ga-PSMA-11 PET/CT brain imaging is a potentially useful imaging tool. The use of 68Ga-PSMA-11 brain PET/CT in evaluation of recurrent glioma seems promising. Absence of physiological uptake of 68Ga-PSMA-11 in the normal brain parenchyma results in high TBR values and consequently better visualization of glioma lesions.

Từ khóa


Tài liệu tham khảo

1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81

1998, Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen, Cancer, 83, 2259, 10.1002/(SICI)1097-0142(19981201)83:11<2259::AID-CNCR5>3.0.CO;2-T

2004, Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer, J Cell Biochem, 91, 528, 10.1002/jcb.10661

2012, 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging, Bioconjug Chem, 23, 688, 10.1021/bc200279b

2015, The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6

2015, Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153

2016, 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT, Clin Nucl Med, 41, 515, 10.1097/RLU.0000000000001197

2016, Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1400, 10.1007/s00259-016-3346-0

2016, (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, 34, 10.1007/s00259-015-3188-1

2017, 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, 44, 1014, 10.1007/s00259-017-3670-z

2014, (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma, Eur J Nucl Med Mol Imaging, 41, 1461, 10.1007/s00259-014-2766-y

2016, (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma, Eur J Nucl Med Mol Imaging, 43, 795, 10.1007/s00259-015-3297-x

2016, PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer?, Clin Nucl Med, 41, e263, 10.1097/RLU.0000000000001148

2016, Elevated 68Ga prostate-specific membrane antigen activity in metastatic non-small cell lung cancer, Clin Nucl Med, 41, 414, 10.1097/RLU.0000000000001139

2016, Follicular lymphoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT, Clin Nucl Med, 41, 500, 10.1097/RLU.0000000000001169

2016, Rectal carcinoma on 68Ga-PSMA PET/CT, Clin Nucl Med, 41, e167, 10.1097/RLU.0000000000001072

2017, 68Ga-PSMA uptake in an incidentally detected gastrointestinal stromal tumor in a case of suspected carcinoma prostate, Clin Nucl Med, 42, e447, 10.1097/RLU.0000000000001774

1999, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature, Cancer Res, 59, 3192

1999, Prostate-specific membrane antigen is produced in tumor-associated neovasculature, Clin Cancer Res, 5, 2674

2014, Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases, Cancer Cell Int, 14, 26, 10.1186/1475-2867-14-26

2017, Diagnostic value of 68Ga PSMA-11 PET/CT imaging of brain tumors-preliminary analysis, Clin Nucl Med, 42, e41, 10.1097/RLU.0000000000001451

2016, Preparation of [(68)Ga]PSMA-11 for PET-CT imaging using a manual synthesis module and organic matrix based (68)Ge/(68)Ga generator, Nucl Med Biol, 43, 463, 10.1016/j.nucmedbio.2016.05.006

2006, Epidemiology and molecular pathology of glioma, Nat Clin Pract Neurol, 2, 494, 10.1038/ncpneuro0289

2012, F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI, Eur J Radiol, 81, 508, 10.1016/j.ejrad.2011.01.080

2015, Modern brain tumor imaging, Brain Tumor Res Treat, 3, 8, 10.14791/btrt.2015.3.1.8

2010, Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences, Nucl Med Biol, 37, 727, 10.1016/j.nucmedbio.2010.04.185

2013, Overview of PET tracers for brain tumor imaging, PET Clin, 8, 129, 10.1016/j.cpet.2013.02.001

2012, Gallium-68: a new trend in PET radiopharmacy, Curr Radiopharm, 5, 142, 10.2174/1874471011205020142

2014, (68)Ga-PRGD2 PET/CT in the evaluation of glioma: a prospective study, Mol Pharm, 11, 3923, 10.1021/mp5003224

2015, Tumor-associated macrophages in glioblastoma multiforme-a suitable target for somatostatin receptor-based imaging and therapy?, PLoS One, 10, e0122269, 10.1371/journal.pone.0122269

2005, Tumour vascular targeting, Nat Rev Cancer, 5, 436, 10.1038/nrc1627

2011, Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme, Arch Pathol Lab Med, 135, 1486, 10.5858/arpa.2010-0740-OA

2015, In vivo visualization of prostate-specific membrane antigen in glioblastoma, Eur J Nucl Med Mol Imaging, 42, 170, 10.1007/s00259-014-2921-5

2017, Prostate-specific membrane antigen-targeted imaging with [18F]DCFPyL in high-grade gliomas, Clin Nucl Med, 42, e433, 10.1097/RLU.0000000000001769

2018, Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody, J Neurooncol

2017, The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?, Neuro Oncol, 19, 1698, 10.1093/neuonc/nox172

Thông tin
Thông tin xuất bản

Clinical Nuclear Medicine

Tập 43 Số 9

e304-e309

Thông tin tác giả